Remsima 120 mg solution for injection in Pre-filled pen – patient leaflet, side effects, dosage

1. What Remsima is and what it is used for

Remsima contains the active substance infliximab. Infliximab is a monoclonal antibody - a

type of protein that attaches to a specific target in the body called TNF (tumour necrosis

factor) alpha.

Remsima belongs to a group of medicines called ‘TNF blockers’. It is used in adults for the

following inflammatory diseases:

• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis (Bechterew’s disease)
• Psoriasis.
• Crohn’s disease
• Ulcerative colitis.

Remsima works by selectively attaching to TNF alpha and blocking its action. TNF alpha is

involved in inflammatory processes of the body so blocking it can reduce the inflammation

in your body.

Rheumatoid arthritis

Rheumatoid arthritis is an inflammatory disease of the joints. If you have active rheumatoid

arthritis you will first be given other medicines. If these medicines do not work well enough,

you will be given Remsima which you will take with another medicine called methotrexate to:

• reduce the signs and symptoms of your disease,
• slow down the damage in your joints,
• improve your physical function.

Psoriatic arthritis

Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis.

If you have active psoriatic arthritis you will first be given other medicines. If these medicines

do not work well enough, you will be given Remsima to:

• reduce the signs and symptoms of your disease,
• slow down the damage in your joints,
• improve your physical function.

Ankylosing spondylitis (Bechterew’s disease)

Ankylosing spondylitis is an inflammatory disease of the spine. If you have ankylosing

spondylitis you will first be given other medicines. If these medicines do not work well

enough, you will be given Remsima to:

• reduce the signs and symptoms of your disease,
• improve your physical function.

Psoriasis

Psoriasis is an inflammatory disease of the skin. If you have moderate to severe plaque

psoriasis, you will first be given other medicines or treatments, such as phototherapy. If

these medicines or treatments do not work well enough, you will be given Remsima to

reduce the signs and symptoms of your disease.

Ulcerative colitis

Ulcerative colitis is an inflammatory disease of the bowel. If you have ulcerative colitis you

will first be given other medicines. If these medicines do not work well enough, you will be

given Remsima to treat your disease.

Crohn’s disease

Crohn’s disease is an inflammatory disease of the bowel. If you have Crohn’s disease you will

first be given other medicines. If these medicines do not work well enough, you will be

given Remsima to:

• treat active Crohn’s disease,

• reduce the number of abnormal openings (fistulae) between your bowel and your skin

  that have not been controlled by other medicines or surgery.

2. What you need to know before you use Remsima

You must not use Remsima if

• you are allergic to infliximab or any of the other ingredients of this medicine (listed in

  section 6),

• you are allergic to proteins that come from mice,

• you have tuberculosis (TB) or another serious infection such as pneumonia or sepsis

  (serious bacterial infection of the blood),

• you have heart failure that is moderate or severe.

Do not use Remsima if any of the above applies to you. If you are not sure, talk to your

doctor before you are given Remsima.

Warnings and precautions

Talk to your doctor before or during treatment with Remsima, if you have:

Had treatment with any medicine containing infliximab before

• Tell your doctor if you have had treatment with medicines containing infliximab in the

  past and are now starting Remsima treatment again.

• If you have had a break in your treatment with infliximab of more than 16 weeks, there is

  a higher risk for allergic reactions when you start the treatment again.

Local injection site reactions

• Some patients receiving infliximab via injection under the skin have experienced local

  injection site reactions. Signs of a local injection site reaction can include redness, pain,

  itching, swelling, hardness, bruising, bleeding, cold sensation, tingling sensation,

  irritation, rash, ulcer, hives, blisters and scab on the skin of the injection site.

• Most of these reactions are mild to moderate and mostly resolve on their own within a

  day.

Infections

• Tell your doctor before you are given Remsima if you have an infection even if it is a very

  minor one.

• Tell your doctor before you are given Remsima if you have ever lived in or travelled to an

  area where infections called histoplasmosis, coccidioidomycosis, or blastomycosis are

  common. These infections are caused by specific types of fungi that can affect the lungs

  or other parts of your body.

• You may get infections more easily when you are being treated with Remsima. If you are

  65 years of age or older, you have a greater risk.

• These infections may be serious and include tuberculosis, infections caused by viruses,

  fungi, bacteria or other organisms in the environment and sepsis that may be life-threat-

  ening.

Tell your doctor straight away if you get signs of infection during treatment with Remsima.

Signs include fever, cough, flu-like signs, feeling unwell, red or hot skin, wounds or dental

problems. Your doctor may recommend temporarily stopping Remsima.

Tuberculosis (TB)

• It is very important that you tell your doctor if you have ever had TB or if you have been in

  close contact with someone who has had or has TB.

• Your doctor will test you to see if you have TB. Cases of TB have been reported in patients

  treated with infliximab, even in patients who have already been treated with medicines

  for TB. Your doctor will record these tests on your patient reminder card.

• If your doctor feels that you are at risk for TB, you may be treated with medicines for TB

  before you are given Remsima.

Tell your doctor straight away if you get signs of TB during treatment with Remsima. Signs

include persistent cough, weight loss, feeling tired, fever, night sweats.

Hepatitis B virus

• Tell your doctor before you are using Remsima if you are a carrier of hepatitis B or have

  ever had it.

  • Tell your doctor if you think you might be at risk of contracting hepatitis B.
  • Your doctor should test you for hepatitis B virus.

  • Treatment with TNF blockers such as Remsima may result in reactivation of hepatitis B

    virus in patients who carry this virus, which can be life-threatening in some cases.

  • If you experience reactivation of hepatitis B, your doctor may need to stop your treatment

    and may give you medicines such as effective antiviral therapy with supportive treatment.

Heart problems

• Tell your doctor if you have any heart problems, such as mild heart failure.
• Your doctor will want to closely monitor your heart.

Tell your doctor straight away if you get new or worsening signs of heart failure during

treatment with Remsima. Signs include shortness of breath or swelling of your feet.

Cancer and lymphoma

• Tell your doctor before you are given Remsima if you have or have ever had lymphoma (a

  type of blood cancer) or any other cancer.

• Patients with severe rheumatoid arthritis, who have had the disease for a long time, may

  be at higher risk of developing lymphoma.

• Patients taking Remsima may have an increased risk of developing lymphoma or another

  cancer.

• Some patients who have received TNF-blockers, including infliximab have developed a

  rare type of cancer called hepatosplenic T-cell lymphoma. Of these patients, most were

  teenage boys or young men and most had either Crohn’s disease or ulcerative colitis. This

  type of cancer has usually resulted in death. Almost all patients had also received

  medicines containing azathioprine or mercaptopurine in addition to TNF-blockers.

• Some patients treated with infliximab have developed certain kinds of skin cancer. If

  there are any changes in your skin or growths on the skin during or after therapy, tell your

  doctor.

• Some women being treated for rheumatoid arthritis with infliximab have developed

  cervical cancer. For women taking Remsima including those over 60 years of age, your

  doctor may recommend regular screening for cervical cancer.

Lung disease or heavy smoking

• Tell your doctor before you are given Remsima if you have a lung disease called chronic

  obstructive pulmonary disease (COPD) or if you are a heavy smoker.

• Patients with COPD and patients who are heavy smokers may have a higher risk of

  developing cancer with Remsima treatment.

Nervous system disease

• Tell your doctor before you are given Remsima if you have or have ever had a problem

  that affects your nervous system. This includes multiple sclerosis, Guillain-Barré syndrome,

  if you have fits or have been diagnosed with ‘optic neuritis’.

Tell your doctor straight away if you get symptoms of a nerve disease during treatment with

Remsima. Signs include changes in your vision, weakness in your arms or legs, numbness or

tingling in any part of your body.

Abnormal skin openings

• Tell your doctor if you have any abnormal skin openings (fistulae) before you are given

  Remsima.

Vaccinations

• Talk to your doctor if you recently have had or are due to have a vaccine.

• You should receive recommended vaccinations before starting Remsima treatment. You

  may receive some vaccines during treatment with Remsima but you should not receive

  live vaccines (vaccines that contain a living but weakened infectious agent) while using

  Remsima because they may cause infections.

• If you received Remsima while you were pregnant, your baby may also be at higher risk

  for getting an infection as a result of receiving a live vaccine during the first year of life. It

  is important that you tell your baby's doctors and other health care professionals about

  your Remsima use so they can decide when your baby should receive any vaccine,

  including live vaccines such as the BCG vaccine (used to prevent tuberculosis).

• If you are breast-feeding, it is important that you tell your baby’s doctors and other

  healthcare professionals about your Remsima use before your baby is given any vaccine.

  For more information see section on Pregnancy and breast-feeding.

Therapeutic infectious agents

• Talk to your doctor if you have recently received or are scheduled to receive treatment with

  a therapeutic infectious agent (such as BCG instillation used for the treatment of cancer).

Operations or dental procedures

• Tell your doctor if you are going to have any operations or dental procedures.

• Tell your surgeon or dentist that you are having treatment with Remsima by showing

  them your patient reminder card.

Liver problems

• Some patients receiving infliximab have developed serious liver problems.

• Tell your doctor straight away if you get symptoms of liver problems during treatment

  with Remsima. Signs include yellowing of the skin and eyes, dark-brown coloured urine,

  pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or

  fever.

Low blood counts

• In some patients receiving infliximab, the body may not make enough of the blood cells

  that help fight infections or help stop bleeding.

• Tell your doctor straight away if you get symptoms of low blood counts during treatment

  with Remsima. Signs include persistent fever, bleeding or bruising more easily, small red

  or purple spots caused by bleeding under the skin, or looking pale.

Immune system disorder

• Some patients receiving infliximab have developed symptoms of an immune system

  disorder called lupus.

• Tell your doctor straight away if you develop symptoms of lupus during treatment with

  Remsima. Signs include joint pain or a rash on cheeks or arms that is sensitive to the sun.

Children and adolescents

Do not give this medicine to children and adolescents under 18 years of age because there

are no data that show that this medicine is safe and works in this age group.

Other medicines and Remsima

Patients who have inflammatory diseases already take medicines to treat their problem.

These medicines may cause side effects. Your doctor will advise you what other medicines

you must keep using while you are having Remsima.

Tell your doctor if you are using, have recently used or might use any other medicines,

including any other medicines to treat Crohn’s disease, ulcerative colitis, rheumatoid

arthritis, ankylosing spondylitis, psoriatic arthritis or psoriasis or medicines obtained without

a prescription, such as vitamins and herbal medicines.

In particular, tell your doctor if you are using any of the following medicines:

• Medicines that affect your immune system.
• Kineret (which contains anakinra). Remsima and Kineret should not be used together.
• Orencia (which contains abatacept). Remsima and Orencia should not be used together.

While using Remsima you should not receive live vaccines. If you were using Remsima

during pregnancy or if you are receiving Remsima while breast-feeding, tell your baby’s

doctor and other health care professionals caring for your baby about your Remsima use

before the baby receives any vaccines.

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse

before using Remsima.

Pregnancy, breast-feeding and fertility

• If you are pregnant or breast-feeding, think you may be pregnant or are planning to have

  a baby, ask your doctor for advice before taking this medicine. Remsima should only be

  used during pregnancy or while breast-feeding if your doctor feels it is necessary for you.

• You should avoid getting pregnant when you are being treated with Remsima and for 6

  months after you stop being treated with it. Discuss the use of contraception during this

  time with your doctor.

• Do not breast-feed when you are being treated with Remsima or for 6 months after your

  last treatment with Remsima.

• If you received Remsima during your pregnancy, your baby may have a higher risk for

  getting an infection.

• It is important that you tell your baby’s doctors and other healthcare professionals about

  your Remsima use before your baby is given any vaccine. If you received Remsima while

  pregnant, giving BCG vaccine (used to prevent tuberculosis) to your baby within 12

  months after birth may result in infection with serious complications, including death.

  Live vaccines such as the BCG vaccine should not be given to your baby within 12 months

  after birth, unless your baby’s doctor recommends otherwise. For more information see

  section on vaccination.

• If you are breast-feeding, it is important that you tell your baby’s doctors and other

  healthcare professionals about your Remsima use before your baby is given any vaccine.

  Live vaccines should not be given to your baby while you are breast-feeding unless your

  baby’s doctor recommends otherwise.

• Severely decreased numbers of white blood cells have been reported in infants born to

  women treated with infliximab during pregnancy. If your baby has continual fevers or

  infections, contact your baby’s doctor immediately.

Driving and using machines

Remsima is not likely to affect your ability to drive or use tools or machines. If you feel tired,

dizzy, or unwell after having Remsima, do not drive or use any tools or machines.

Remsima contains sodium and sorbitol

This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially

‘sodium-free’ and 45 mg sorbitol in each 120 mg dose.

Package leaflet: Information for the user

Remsima 120 mg solution for injection in pre-filled pen infliximab

3. How to use Remsima

Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

Rheumatoid arthritis

Your doctor will start your treatment with or without two Remsima intravenous infusion doses of 3 mg Your doctor will start your treatment with or without two infliximab intravenous infusion doses of 3 mg for every kg of body weight (given to you into a vein, usually in your arm, over a period of 2 hours). If infliximab intravenous infusion doses are given to start the treatment, they are administered 2 weeks apart via intravenous infusion. After 4 weeks from the last intravenous infusion, you will be given Remsima via injection under the skin (subcuta-neous injection). If Remsima subcutaneous injection doses are given to start the treatment,

Remsima 120 mg should be given as a subcutaneous injection followed by additional subcutaneous injections at 1, 2, 3 and 4 weeks after the first injection, then every 2 weeks thereafter.

The usual recommended dose of Remsima subcutaneous injection is 120 mg once every 2 weeks regardless of weight.

Psoriatic arthritis, ankylosing spondylitis (Bechterew’s disease) and psoriasis

Your doctor will start your treatment with two infliximab intravenous infusion doses of 5 mg for every kg of body weight (given to you into a vein, usually in your arm, over a period of 2 hours). They are administered 2 weeks apart via intravenous infusion. After 4 weeks from the last intravenous infusion, you will be given Remsima via injection under the skin (subcutane-ous injection).

The usual recommended dose of Remsima subcutaneous injection is 120 mg once every 2 weeks regardless of weight.

Crohn’s disease and ulcerative colitis

Your doctor will start your treatment with two or three infliximab intravenous infusion doses of 5 mg for every kg of body weight (given to you into a vein, usually in your arm, over a period of 2 hours). They are administered 2 weeks apart via intravenous infusion and additional intravenous infusion may be given 4 weeks after the second infusion. After 4 weeks from the last intravenous infusion, you will be given Remsima via injection under the skin (subcutaneous injection).

The usual recommended dose of Remsima subcutaneous injection is 120 mg once every 2 weeks regardless of weight.

How Remsima is given

• Remsima 120 mg solution for injection is administered by injection under the skin

  (subcutaneous use) only. It is important to check the product labels to ensure that the correct formulation is being given as prescribed.

• For patients with rheumatoid arthritis, your doctor may start your Remsima treatment with or without infliximab intravenous infusion doses. For patients with ankylosing spondylitis, psoriatic arthritis or psoriasis, two infliximab intravenous infusion doses will be given to start your Remsima treatment. For patients with Crohn’s disease or ulcerative colitis, two or three infliximab intravenous infusion doses will be given to start your

  Remsima treatment.

• For rheumatoid arthritis patients, if Remsima treatment is initiated without two infliximab intravenous infusion doses, the table below shows how often you will usually have

  Remsima 120 mg subcutaneous after your first dose.

• Infliximab intravenous infusion doses will be given 2 weeks apart by your doctor or nurse and additional intravenous infusion may be given 4 weeks after the second infusion for

  Crohn’s disease and ulcerative colitis under your doctor’s discretion to start your Remsima treatment. The first Remsima subcutaneous injection will be given 4 weeks after the last intravenous infusion followed by Remsima subcutaneous injections given every 2 weeks.

• The first subcutaneous injection of Remsima will be administered under the supervision of your doctor.
• After proper training, if you feel you are well-trained and confident to inject Remsima yourself, your doctor may allow you to inject subsequent doses of Remsima yourself at home.
• Talk to your doctor if you have any questions about giving yourself an injection. You will find detailed “Instructions for Use” at the end of this leaflet.

If you use more Remsima than you should

If you have used more Remsima than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor, pharmacist or nurse immediately.

Always have the outer carton of the medicine with you, even if it is empty.

If you forget to use Remsima

Missed dose for up to 7 days

If you miss a dose of Remsima for up to 7 days, after the original scheduled dose, you should take the missed dose immediately. Take your next dose on the next originally planned date and then follow the original dosing schedule.

Missed dose for 8 days or more

If you miss a dose of Remsima for 8 days or more, after the original scheduled dose, you should not take the missed dose. Take your next dose on the next originally planned date and then follow the original dosing schedule.

If you are not sure when to inject Remsima, call your doctor.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Most side effects are mild to moderate. However some patients may experience serious side effects and may require treatment. Side effects may also occur after your treatment with

Remsima has stopped.

Tell your doctor straight away if you notice any of the following:

• Signs of an allergic reaction such as swelling of your face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. Some of these reactions may be serious or life-threatening. An allergic reaction could happen within 2 hours of your injection or later. More signs of allergic side effects that may happen up to 12 days after your injection include pain in the muscles, fever, joint or jaw pain, sore throat or headache.
• Signs of a local injection site reaction such as redness, pain, itching, swelling, hardness, bruising, bleeding, cold sensation, tingling sensation, irritation, rash, ulcer, hives, blisters and scab.

• Signs of a heart problem such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea

  (feeling sick), vomiting, fluttering or pounding in your chest, a fast or a slow heartbeat, and swelling of your feet.

• Signs of infection (including TB) such as fever, feeling tired, cough which may be persistent, shortness of breath, flu-like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental problems or burning sensation when urinating.
• Possible signs of cancer including but not limited to swelling of lymph nodes, weight loss, fever, unusual skin nodules, changes in moles or skin colouring, or unusual vaginal bleeding.
• Signs of a lung problem such as coughing, breathing difficulties or tightness in the chest.

• Signs of a nervous system problem (including eye problems) such as signs of a stroke

  (sudden numbness or weakness of your face, arm or leg, especially on one side of your body; sudden confusion, trouble speaking or understanding; trouble seeing in one or both eyes, trouble walking, dizziness, loss of balance or coordination or a severe headache), fits, tingling/numbness in any part of your body, or weakness in arms or legs, changes in eyesight such as double vision or other eye problems.

• Signs of a liver problem (including hepatitis B infection when you have had hepatitis B in the past) such as yellowing of the skin or eyes, dark-brown coloured urine, pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever.

• Signs of an immune system disorder called lupus such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash

  (sarcoidosis).

• Signs of low blood counts such as persistent fever, bleeding or bruising more easily, small red or purple spots caused by bleeding under the skin, or looking pale.
• Signs of serious skin problems such as reddish-target-like spots or circular patches often with central blisters on the trunk, large areas of peeling and shedding (exfoliating) skin, ulcers of mouth, throat, nose, genitals and eyes or small pus-filled bumps that can spread over the body. These skin reactions can be accompanied by fever.

Tell your doctor straight away if you notice any of the above.

The following side effects have been observed with Remsima:

Very common: may affect more than 1 in 10 people

• Stomach pain, feeling sick
• Viral infections such as herpes or flu
• Upper respiratory infections such as sinusitis
• Headache

• Side effect due to an injection

  2^nd dose

  3^rd dose

  4^th dose

  5^th dose

  Further doses

  1 week after your 1^st dose

  2 weeks after your 1^st dose

  3 weeks after your 1^st dose

  4 weeks after your 1^st dose

  6 weeks after your 1^st dose and every 2 weeks thereafter LM284907-LE001

• Start the injection (see Figure F).

  a. Press the pen firmly against the skin.

  Note: When the injection starts you will hear the 1st loud “click” and the purple plunger rod will begin to fill the window.

  b. Keep holding the pen firmly against the skin and listen for the 2nd loud “click.”

  This can take up to 10 seconds.

  Note: Do not change the position of the pre-filled pen after the injection has started.

  c. After you hear the second loud “click” continue to hold the pre-filled pen firmly against the skin and count slowly to 5 to make sure you inject the full dose.

• Remove the pen from your skin.

  a. Look at the pen and confirm that the purple plunger rod is filling the window completely.

  b. Remove the pre-filled pen from your skin

  (see Figure G).

  Note: After you remove the pen from the injection site, the needle will be automatically covered (see Figure H).

  Note: If the window has not turned completely purple or if the medicine is still injecting, this means you have not received a full dose.

  Call your healthcare provider immediately.

  Note: You may see grey stopper in the Window.

  This is normal. Some bleeding may occur.

  Do not reuse the pen. Do not rub the injection site.

  After the injection

• Throw away (dispose of) the pre-filled pen.

  a. Put the used pen in an approved sharps disposal container immediately after use (see Figure I).

  Note: Do not throw away (dispose of) the pre-filled pen in your household trash.

  b. If you do not have an approved sharps disposal container, you may use a household container that is:

  • made of a heavy-duty plastic;
  • able to close with a tight-fitting, puncture resistant lid, without sharps being able to come out;
  • upright and stable during use;
  • leak-resistant; and
  • properly labelled to warn of hazardous waste inside the container.

c. When your sharps disposal container is almost full, it should be disposed of in accordance with local requirements.

Do not recap the pen.

Note: Keep the pen and sharps disposal container out of the sight and reach of children.

1. 13.

   Care for the injection site.

   a. Treat the injection site by gently pressing, not rubbing, a cotton ball or gauze to the site and apply an adhesive bandage, if necessary. Uxbridge, UB8 1JG

United Kingdom

Manufacturer

Nuvisan France SARL

2400, Route des Colles,

06410, Biot,

France

For any information about this medicine, please contact the Marketing Authorisation Holder:

United Kingdom

Celltrion Healthcare United Kingdom Limited

Tel: +44 (0) 1753 983 500

This leaflet was last revised in 06/2026.

1. 7. Instructions for use

Read carefully these instructions before using the Remsima pen. Consult your healthcare

provider if you have questions about using the Remsima pen.

Important information

• Use the pen ONLY if your healthcare provider has trained you on the right way to prepare

  for and to give an injection.

• Ask your healthcare provider how often you will need to give an injection.

• Rotate the injection site each time you give an injection. Each new injection site should

  be at least 3 cm away from the previous injection site.

• Do not use the pen if it has been dropped or is visibly damaged. A damaged pen may not

  function properly.

• Do not reuse the pen.

• Do not shake the pen at any time.

  About the Remsima pen

Parts of the pen (see Figure A):

• Do not remove the cap until you are ready to inject. Once you remove the cap, do not

  recap the pen.

  Prepare for the injection

• Gather the supplies for the injection.

  a. Prepare a clean, flat surface, such as a table or countertop, in a well-lit area.

  b. Remove the pen from the carton stored in your refrigerator.

  c. Ensure you have the following supplies:

  • Pen
  • Alcohol swab
  • Cotton ball or gauze*
  • Adhesive bandage*
  • Sharps disposal container*

* Items not included in the carton.

1. 2.

   Inspect the pen.

   Do not use the pen if:

   • It is cracked or damaged.
   • The expiration date has passed.
2. 3.

   Inspect the medicine (see Figure B).

   The liquid should be clear and colourless

   to pale brown. Do not use the pen if the liquid

   is cloudy, discoloured or contains particles in it.

   Note: You may see air bubbles in the liquid.

   This is normal.

3. 4.

   Wait 30 minutes.

   a. Leave the pen at room temperature for 30 minutes to allow it to naturally warm up.

   Do not warm the pen using heat sources such as hot water or a microwave.

4. 5.

   Choose an injection site (see Figure C).

   a. Select an injection site. You may inject into:

   • The front of the thighs.

   • The abdomen except for the 5 cm around

     the belly button (navel).

   • The outer area of the upper arms

     (caregiver ONLY).

Do not inject into skin that is within 5 cm of

your belly button (navel), or is tender, damaged,

bruised, or scarred.

Note: Rotate the injection site each time you give

an injection. Each new injection site should be

at least 3 cm away from the previous injection site.

1. 6.

   Wash your hands.

   a. Wash your hands with soap and water and dry them thoroughly.

2. 7.

   Clean the injection site.

   a. Clean the injection site with an alcohol swab.

   b. Let the skin dry before injecting.

   Do not blow on or touch the injection site again before giving the injection.

   Give the injection

3. 8.

   Remove the cap (see Figure D).

   a. Pull the cap straight off and set it aside.

   Do not recap the pen.

   Do not remove the Cap until you are ready to inject.

   Do not touch the needle cover.

   Doing so may result in a needle stick injury.

   Note: It is normal to see a few drops of liquid c

   ome out of the needle upon the cap removal.

   b. Throw away (dispose of) the cap in

   a sharps container (see Step 12 and Figure I).

4. 9.

   Place the pen on the injection site (see Figure E).

   a. Hold the pen so that you can see the window.

   b. Without pinching or stretching the skin,

   place the pen over the injection site at

   a 90-degree angle.

5. • Pain.

Common: may affect up to 1 in 10 people

• Changes in how your liver works, increase in liver enzymes (shown in blood tests)
• Lung or chest infections such as bronchitis or pneumonia
• Difficult or painful breathing, chest pain
• Bleeding in the stomach or intestines, diarrhoea, indigestion, heartburn, constipation
• Nettle-type rash (hives), itchy rash or dry skin
• Balance problems or feeling dizzy
• Fever, increased sweating
• Circulation problems such as low or high blood pressure
• Bruising, hot flush or nosebleed, warm, red skin (flushing)
• Feeling tired or weak
• Bacterial infections such as blood poisoning, abscess or infection of the skin (cellulitis)
• Infection of the skin due to a fungus
• Blood problems such as anaemia or low white blood cell count
• Swollen lymph nodes
• Depression, problems sleeping
• Eye problems, including red eyes and infections
• Fast heart beat (tachycardia) or palpitations
• Pain in the joints, muscles or back
• Urinary tract infection
• Psoriasis, skin problems such as eczema and hair loss
• Reactions at the injection site such as pain, swelling, redness or itching
• Chills, a build-up of fluid under the skin causing swelling
• Feeling numb or having a tingling feeling.

Uncommon: may affect up to 1 in 100 people

• Shortage of blood supply, swelling of a vein
• Collection of blood outside the blood vessels (haematoma) or bruising

• Skin problems such as blistering, warts, abnormal skin colouration or pigmentation, or

  swollen lips, or thickening of the skin, or red, scaly, and flaky skin

• Severe allergic reactions (e.g. anaphylaxis), an immune system disorder called lupus,

  allergic reactions to foreign proteins

• Wounds taking longer to heal
• Swelling of the liver (hepatitis) or gall bladder, liver damage
• Feeling forgetful, irritable, confused, nervous
• Eye problems including blurred or reduced vision, puffy eyes or sties
• New or worsening heart failure, slow heart rate
• Fainting
• Convulsions, nerve problems
• A hole in the bowel or blockage of the intestine, stomach pain or cramps
• Swelling of your pancreas (pancreatitis)
• Fungal infections such as yeast infection, or fungal infection of the nails
• Lung problems (such as oedema)
• Fluid around the lungs (pleural effusion)
• Narrowed airway in the lungs, causing difficulty breathing

• Inflamed lining of the lung, causing sharp chest pains that feel worse with breathing

  (pleurisy)

• Tuberculosis
• Kidney infections
• Low platelet count, too many white blood cells
• Infections of the vagina
• Blood test result showing ‘antibodies’ against your own body.
• Changes in cholesterol and fat levels in the blood.
• Weight gain (for most patients, the weight gain was small).

Rare: may affect up to 1 in 1,000 people

• A type of blood cancer (lymphoma)

• Your blood not supplying enough oxygen to your body, circulation problems such as

  narrowing of a blood vessel

• Inflammation of the lining of the brain (meningitis)
• Infections due to a weakened immune system
• Hepatitis B infection when you have had hepatitis B in the past
• Inflamed liver caused by a problem with the immune system (autoimmune hepatitis)
• Liver problem that causes yellowing of the skin or eyes (jaundice)
• Abnormal tissue swelling or growth

• Severe allergic reaction that may cause loss of consciousness and could be

  life-threatening (anaphylactic shock)

• Swelling of small blood vessels (vasculitis)
• Immune disorders that could affect the lungs, skin and lymph nodes (such as sarcoidosis)

• Collections of immune cells resulting from an inflammatory response (granulomatous

  lesions)

• Lack of interest or emotion

• Serious skin problems such as toxic epidermal necrolysis, Stevens-Johnson syndrome and

  acute generalised exanthematous pustulosis

• Other skin problems such as erythema multiforme, blisters and peeling skin, or boils

  (furunculosis)

• Serious nervous system disorders such as transverse myelitis, multiple sclerosis-like

  disease, optic neuritis and Guillain-Barré syndrome

• Inflammation in the eye that may cause changes in the vision, including blindness
• Fluid in the lining of the heart (pericardial effusion)
• Serious lung problems (such as interstitial lung disease)
• Melanoma (a type of skin cancer)
• Cervical cancer
• Low blood counts, including a severely decreased number of white blood cells.
• Small red or purple spots caused by bleeding under the skin

• Abnormal values of a blood protein called ‘complement factor’ which is part of the

  immune system

• Lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on

  mucous membranes).

Not known: frequency cannot be estimated from the available data

• Cancer
• A rare blood cancer affecting mostly young men (hepatosplenic T-cell lymphoma)
• Liver failure
• Merkel cell carcinoma (a type of skin cancer)

• Kaposi’s sarcoma, a rare cancer related to infection with human herpes virus 8. Kaposi’s

  sarcoma most commonly appears as purple lesions on the skin.

• Worsening of a condition called dermatomyositis (seen as a skin rash accompanying

  muscle weakness)

• Heart attack
• Stroke
• Temporary loss of sight during or within 2 hours of infusion
• Infection due to a live vaccine because of a weakened immune system.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any

possible side effects not listed in this leaflet. You can also report side effects directly via

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play

or Apple App Store.

By reporting side effects you can help provide more information on the safety of this

medicine.

5. How to store Remsima

• Keep this medicine out of the sight and reach of children.

• Do not use this medicine after the expiry date which is stated on the label and the carton

  after “EXP”. The expiry date refers to the last day of that month.

• Store in a refrigerator (2°C - 8°C). Do not freeze. Keep the pre-filled pen in the outer carton

  in order to protect from light.

• This medicine can also be stored in the original carton outside of refrigerated storage up

  to a maximum of 25°C for a single period of up to 28 days, but not beyond the original

  expiry date. In this situation, do not return to refrigerated storage again. Write the new

  expiry date on the carton including day/month/year. Discard this medicine if not used by

  the new expiry date or the expiry date printed on the carton, whichever is earlier.

• Do not throw away any medicines via wastewater or household waste. Ask your

  pharmacist how to throw away medicines you no longer use. These measures will help

  protect the environment.

6. Contents of the pack and other information

What Remsima contains

• The active substance is infliximab. Each 1 ml single dose pre-filled pen contains 120 mg of

  infliximab.

• The other ingredients are acetic acid, sodium acetate trihydrate, sorbitol, polysorbate 80

  and water for injections.

What Remsima looks like and contents of the pack

Remsima is a clear to opalescent, colourless to pale brown solution which is supplied as a

single use pre-filled pen.

Remsima 120 mg solution for injection in pre-filled pen with 27-gauge staked needle,

purple plunger rod is supplied in pack containing 2 pre-filled pens with 2 alcohol pads.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Celltrion Healthcare United Kingdom Limited

The Charter Building, Charter Place,

Figure A Before Use

After Use

Body

Window

Cap Needle

Cover

Medicine Plunger

Rod

Figure B

Figure C = Self-injection and Caregiver

= Caregiver ONLY

Front

Needle

Cover

Figure D

Figure E 90°

Figure F first second

Count slowly to 5

10Sec

5Sec

Injection is ongoing

End of Injection Start of Injection

Needle

Cover

Figure H Figure G

Figure I